Topic / Other MS News

Research into Ocrelizumab's impact on multiple sclerosis

For the ten per cent of patients diagnosed with primary progressive MS, research into Ocrelizumab's impact on multiple sclerosis will be of great interest.

For the 10 per cent of patients diagnosed with primary progressive MS, and for whom there has to date been no effective treatment, results from a huge clinical trial for a drug called Ocrelizumab may bring hope.

Administered in the form of an intravenous drip every six months, Ocrelizumab works by stopping the immune cells which attack myelin, from doing so.

In patients with primary progressive Multiple Sclerosis, the data from the trial showed a slowing in the progress of disability by 24 per cent over just 12 weeks compared with patients who took a dummy placebo, and there were also positive results for patients with relapsing-remitting MS who saw a 47 per cent reduction in relapse rate, compared to Rebif.

Ocrelizumab